Filter by Lead Doctor (All Doctors) Alison Conlin, M.D.Robert McKenna, M.D.Timothy Kristedja, M.D.Raul Mena, M.D.Steven O' Day, M.D. Title Physician Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) NCT ID : 02194738 Protocol Number : A151216 Phase : N/A Location : Santa Monica, CA Alison Conlin, M.D. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study NCT ID : 04267848 Protocol Number : A081801 Phase : 3 Location : Santa Monica, CA Alison Conlin, M.D. Evaluating the Clinical Efficacy of an Early-Stage Lung Cancer Detector NCT ID : N/A Protocol Number : CPC001-2017-S5P4-PSJHC Phase : N/A Location : Santa Monica, CA Robert McKenna, M.D. Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) NCT ID : 03425643 Protocol Number : MK-7339-008 Phase : 3 Location : Santa Monica, CA Timothy Kristedja, M.D. A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) (KEYLYNK-008) NCT ID : 03976362 Protocol Number : MK-7339-008 Phase : 3 Location : Burbank, CA Raul Mena, M.D. A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer (KEYLYNK-006) NCT ID : 03976323 Protocol Number : MK-7339-006 Phase : 3 Location : Burbank, CA Raul Mena, M.D. Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) NCT ID : 03425643 Protocol Number : MK-3475-671 Phase : 3 Location : Santa Monica, CA Steven O' Day, M.D.